Biotech News

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis (PSNL)Personalis2026-06-25 13:46 ESTCompany update

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs FREMONT, Calif. --(BUSINESS WIRE)--Jun. 9, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision

Open original release

Related news

PSNLPersonalis2026-06-25 13:46 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

PSNLPersonalis2026-06-25 13:46 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Participate in Upcoming Investor Events

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports First Quarter Results and Recent Highlights

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

View all latest news

Personalis

Personalis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PSNLPersonalis2026-06-26 13:19 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-26 13:19 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-26 13:19 EST

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

PSNLPersonalis2026-06-26 13:19 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-26 13:19 EST

Personalis to Participate in Upcoming Investor Events

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States